Northeast Pharmaceutical Group Co Ltd
Northeast Pharmaceutical Group Co., Ltd. engages in chemical pharmaceuticals preparations, pharmaceutical business, pharmaceutical engineering, biopharmaceuticals, and other businesses in China. It offers vitamin products, such as vitamin C, vitamin B1, vitamin B6, and L-carnitine series; anti-infection products, such as fosfomycin series, azithromycin series, amantadine series, berberine hydroch… Read more
Northeast Pharmaceutical Group Co Ltd (000597) - Total Liabilities
Latest total liabilities as of September 2025: CN¥8.05 Billion CNY
Based on the latest financial reports, Northeast Pharmaceutical Group Co Ltd (000597) has total liabilities worth CN¥8.05 Billion CNY as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Northeast Pharmaceutical Group Co Ltd - Total Liabilities Trend (1993–2024)
This chart illustrates how Northeast Pharmaceutical Group Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Northeast Pharmaceutical Group Co Ltd Competitors by Total Liabilities
The table below lists competitors of Northeast Pharmaceutical Group Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Cooper-Standard Holdings Inc
F:C31
|
Germany | €1.97 Billion |
|
Olectra Greentech Limited
NSE:OLECTRA
|
India | ₹12.39 Billion |
|
Shibaura Machine Co.Ltd
F:TOA
|
Germany | €68.75 Billion |
|
Korea Circuit Co. Ltd.
KO:007810
|
Korea | ₩568.49 Billion |
|
CARE Ratings Limited
NSE:CARERATING
|
India | ₹1.65 Billion |
|
Dream Finders Homes Inc
NYSE:DFH
|
USA | $2.12 Billion |
|
Suzhou K-Hiragawa Electronic Technology Co. Ltd. A
SHG:603052
|
China | CN¥535.12 Million |
|
Canaccord Genuity Group Inc
PINK:CCORF
|
USA | $6.25 Billion |
Liability Composition Analysis (1993–2024)
This chart breaks down Northeast Pharmaceutical Group Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.11 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.50 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.59 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Northeast Pharmaceutical Group Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Northeast Pharmaceutical Group Co Ltd (1993–2024)
The table below shows the annual total liabilities of Northeast Pharmaceutical Group Co Ltd from 1993 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | CN¥8.88 Billion | -12.24% |
| 2023-12-31 | CN¥10.11 Billion | +11.19% |
| 2022-12-31 | CN¥9.10 Billion | +2.34% |
| 2021-12-31 | CN¥8.89 Billion | +10.51% |
| 2020-12-31 | CN¥8.04 Billion | -6.71% |
| 2019-12-31 | CN¥8.62 Billion | +6.11% |
| 2018-12-31 | CN¥8.13 Billion | +1.01% |
| 2017-12-31 | CN¥8.05 Billion | +9.37% |
| 2016-12-31 | CN¥7.36 Billion | +16.92% |
| 2015-12-31 | CN¥6.29 Billion | +8.26% |
| 2014-12-31 | CN¥5.81 Billion | -2.42% |
| 2013-12-31 | CN¥5.96 Billion | +40.36% |
| 2012-12-31 | CN¥4.24 Billion | +2.74% |
| 2011-12-31 | CN¥4.13 Billion | +16.65% |
| 2010-12-31 | CN¥3.54 Billion | -12.05% |
| 2009-12-31 | CN¥4.03 Billion | +59.14% |
| 2008-12-31 | CN¥2.53 Billion | +16.99% |
| 2007-12-31 | CN¥2.16 Billion | +68.91% |
| 2006-12-31 | CN¥1.28 Billion | -8.43% |
| 2005-12-31 | CN¥1.40 Billion | -9.84% |
| 2004-12-31 | CN¥1.55 Billion | -6.13% |
| 2003-12-31 | CN¥1.65 Billion | -8.64% |
| 2002-12-31 | CN¥1.81 Billion | -3.47% |
| 2001-12-31 | CN¥1.87 Billion | +6.18% |
| 2000-12-31 | CN¥1.76 Billion | +1.85% |
| 1999-12-31 | CN¥1.73 Billion | +8.84% |
| 1998-12-31 | CN¥1.59 Billion | +29.30% |
| 1997-12-31 | CN¥1.23 Billion | -41.48% |
| 1996-12-31 | CN¥2.10 Billion | +25.37% |
| 1995-12-31 | CN¥1.68 Billion | +50.97% |
| 1994-12-31 | CN¥1.11 Billion | +5.56% |
| 1993-12-31 | CN¥1.05 Billion | -- |